Drug intelligence / Profile preview

FSC231

Development stage: Preclinical
Lead developer: scPharmaceuticals
Modality: Small Molecules
Administration: Subcutaneous

Overview

FSC231 is a subcutaneous formulation of iron isomaltoside, developed by scPharmaceuticals. It is designed for the treatment of iron deficiency anemia, offering a subcutaneous administration route for a therapy previously limited to intravenous delivery. The drug aims to replenish iron stores in patients with iron deficiency.

Targets

PICK1 (Protein interacting with C kinase 1)

Beyond the preview

Go deeper on FSC231.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FSC231.

Explore the full profile